Baltimore-based AsclepiX Therapeutics raises $5M - Technical.ly Baltimore

Sciences

Nov. 15, 2018 2:05 pm

Baltimore-based AsclepiX Therapeutics raises $5M

The Johns Hopkins spinout is developing a new treatment for leading causes of blindness.
Lab space at Johns Hopkins’ FastForward 1812.

Lab space at Johns Hopkins' FastForward 1812.

(Photo by Stephen Babcock)

Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.

The convertible note round was led by Barer & Son Capital, with participation from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. It brings the company’s total raised to $11 million.

The company was founded by Johns Hopkins biomedical engineering professors Aleksander Popel and Jordan J. Green, who developed peptide products that form the foundation of the company’s treatments.

With a team of four people at JHU’s FastForward space in Remington’s R. House, Ascelpix is developing a treatment for diseases called diabetic macular edema and wet age-related macular degeneration. According to the company, the number of people with the treatment is expected to reach 7 million by 2020.

Currently available treatments require an injection into the eye once a month for several months. AsclepiX Therapeutics’ first treatment, called ATX107, offers the potential for treating the diseases with fewer injections.

“In extensive animal testing, AXT107 was safe and superior to current approved therapies in preventing and even reversing progressive pathologic changes in the retina with just two to three injections per year, a clear benefit in longer duration and less frequent dosing compared to those currently approved therapies,” said AsclepiX Therapeutics CEO Wendy Perrow.

The funding will assist the company as it seeks to complete its application for investigational new drug status with the U.S. Food and Drug Administration. The company is also planning for clinical trials for patients with diabetic macular edema and wet age-related macular degeneration.

With the investment, Barer and Sons Managing Partner Josh Barer, Rapha Capital Management Managing Partner Kevin Slawin, and Sapna Srivastava are joining the company’s board.

“Vision loss is a devastating complication of several common diseases, including diabetes. We’re excited at the potential of AXT107 to help millions avoid this difficult disability while requiring less frequent therapeutic interventions by their ophthalmologists,” Slawin said in a statement.

Advertisement

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Cybrary’s $15M Series B will be used to expand its cybersecurity training platform

Galen Robotics investment shows how the Opportunity Zone program can fund startups

Sonavi Labs raised a $1M seed round. It’s a big milestone for a diverse team

SPONSORED

Baltimore

How this lawyer is helping entrepreneurs bark up the right tree

Philadelphia

Vistar Media

Sr. Software Engineer

Apply Now

Philadelphia

Vistar Media

Front End Engineer

Apply Now

Baltimore, MD

14 West

Qlik Developer

Apply Now

Minnowtech raises $600K seed round, supported by Maryland investors

Camden Partners leads $6M funding round for Techtonic

After winning DataTribe Challenge, Prevailion grows in Maryland

SPONSORED

Baltimore

Get to know SmartLogic’s culture of plants, podcasts and productive client relationships

Baltimore, MD

14 West

Senior Qlik Developer

Apply Now

Baltimore, MD

14 West

Lead Qlik Developer

Apply Now

Baltimore

14 West

Senior Business Analyst

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!